



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 17TH JUNE 2020

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairman)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Dr J Adiyodi (JA)	Consultant Haematologist, ELHT
Dr R Ahmed (RA)	GP BwD CCG

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
-------------	---

2020/037: APOLOGIES:

Mr U Akram	Pharmacist, Lancashire Care Foundation Trust
------------	--

2020/038: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2020/039: MINUTES OF MAR-APRIL Email MEETING:

Accepted as a correct record.

2020/040: MATTERS ARISING:

Not on action sheet:

2020/031: NICE RECOMMENDATIONS (from Feb) – Patiromer – Red Traffic light suggested but to check with renal physicians and also status in Central Lancashire.

From action sheet:

2019/131: Treatment of Vitamin B12 Deficiency Draft – A pathway is currently being developed with Jane Oakey from Path Lab and waiting for active B12 testing in the lab. To be brought to ELMMB when completed.

2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta®

Respiratory consultant to attend July ELMMB to discuss.

2020/020: Formulary Updates - Ranolazine & Ivabradine – Dr Singh to assist with producing a Hot Topic to support GP prescribing.

2020/041: NEW PRODUCT REQUEST – CAVILON ADVANCE (& MEDIDERMA RANGE)

Requested by wound care team and has come into use. To be invited to next meeting to discuss product and place in therapy.

2020/042: NEW PRODUCT REQUEST – GEPAN®

Requested by Mr S Islam, Consultant Urological Surgeon, for interstitial cystitis and other bladder conditions. Gepan® bladder instillation contains chondroitin and it is planned to replace current hyaluronic acid instillations. It is a cost effective preparation with the option for some patients to manage self-administration, reducing clinic attendances. It is approved for specialist use in secondary care to replace hyaluronic bladder instillations.

Resolved: Gepan® added to formulary to for specialist urology use.

Traffic Light: RED

2020/043: NEW PRODUCT REQUEST – MAINTELYTE® SOLUTION FOR INFUSION

Recommended by ELHT Fluid Stewardship Group, as an infusion for fluid replacement. The current ranges of fluids are not always prescribed effectively and have potential safety issues due to range of elements involved. Maintelyte is close to recommended requirements for fluid replacement in NICE CG174. It is simpler to prescribe and cost neutral. The ELHT fluid stewardship group will provide the necessary information/ guidelines and training for the introduction of Maintelyte.

Maintelyte is approved for use in the trust as advised by the ELHT Fluid Stewardship group.

Resolved: Maintelyte added to formulary for use in line with ELHT Fluid

Stewardship group guidance.

Traffic Light: RED

2020/044: NEW PRODUCT REQUEST – WAVESENSE JAZZ BGT STRIPS

Requested by Midwifery for use with Wavesense JAZZ wireless blood glucose meter in gestational diabetes. The meter is compatible with GDM-Health which facilitates remote management of patients with gestational diabetes. The meter is not currently included in the local formulary. Following a recent review the meter was considered cost effective but did not make the final short-list. A concern was raised over potential costs of remote monitoring after the first year. Defer to a future meeting for more information.

Action: Request further information from midwifery Diabetes team.

2020/045: LSCMMG CONSULTATIONS (FOR JULY LSCMMG)

Psoriasis Biologics & High Cost Drug Commissioning Pathway – updated – Dermatology support the recommendations but with the suggestion that they should also be able to prescribe a biologic ‘when high impact sites are affected even if a PASI of 10 is not reached’ (new BAD guidelines will reflect this – currently in draft). They had concerns with the costings tables, which has been raised with LSCMMG who advised that this will not be in the final document.

Rifaximin Small Intestinal Bacterial Overgrowth New Medicines Assessment – gastroenterology support use when standard first, second or third line treatments have either absent or minimal clinical response, or there is drug allergy or intolerance to standard treatments. CCG’s also support recommendation as a red traffic light.

Linezolid tablets change of RAG status – locally RAG status is already Amber to support GP’s prescribing after recommendation by microbiology.

Assessing Suitability for Strong Opioid Use Algorithms – ELMMB was not in favour of this document and felt the existing document was far more comprehensive and helpful to clinicians. They asked for clarity over whether the intention was for this to replace or complement the existing guideline. Comments were also received with respect to possible dosing errors.

Dapagliflozin Prescriber Information Sheet – to support use in type 1 diabetes.

Resolved: Comments to be sent to LSCMMG.

2020/046: LSCMMG Recommendations (From Mar LSCMMG)

None published on website.

2020/047: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS (FEB & MAR)

No meetings held since January.

2020/048: FORMULARY UPDATES

Camouflage creams – locally RED traffic light. Costs in primary care can be difficult to manage, but this is creating practical issues for patients to receive supplies when recommended by the specialist nurse led service. It is now agreed that these will locally remain as RED traffic light with prescriptions from GPs dispensed via the IMOT service.

Combination diabetes products – there are many products available containing combination diabetes medications. These products may offer cost effective and/or improved compliance options for some patients but also have associated risks with fixed doses, unfamiliar names and potential for confusion. A suggestion was made to streamline the choice starting with what is currently in use and considering the actual components to offer a gliptin and a gliflozin option. Suggest review current use and discuss with diabetes specialists then bring back to ELMMB.

Action: Review current use and discuss with diabetes specialists

Famotidine – ranitidine (all forms) will not be available for the foreseeable future. Famotidine is a possible option (although currently some supply issues) for patients when omeprazole or lansoprazole are not appropriate. Change to Amber on formulary.

Traffic Light: AMBER

VitA-POS eye ointment – name has changed to Hylo Night eye ointment.

Excetera cream – name has changed to Epimax Excetera cream.

Resolved: Formulary to be updated as above

2020/049: MANAGED INTRODUCTION OF NEW DRUGS POLICY

The overarching policy for managed introduction of new drugs has been reviewed with updates to the acronyms, terms of reference and process to reflect the current Lancashire position. Comments to LR by the 26th June particularly on the flow chart on page 11 and decision map in Appendix 8 (page 41).

Action: LR to update policy following any comments received by 26th June.

2020/050: ELHT GUIDANCE: PALLIATIVE CARE AND CARE IN THE LAST DAYS OF LIFE DURING COVID-19 OUTBREAK

For information – policy agreed in the trust in line with NICE guidance during the COVID-19 outbreak.

Comment: NICE guidance now updated to include NSAIDs

2020/051: NICE RECOMMENDATIONS (from May)

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer [TA628] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629) is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

Traffic Light: RED

Larotrectinib for treating NTRK fusion-positive solid tumours (TA630) is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

Traffic Light: RED

2020/052: EAMS: REMDESIVIR

Remdesivir is indicated for the treatment of adults and adolescent patients aged ≥ 12 years and weighing at least 40 kg hospitalised with suspected or laboratory confirmed SARS-CoV-2 infection and severe disease. Patients with severe disease are those with an SpO₂ $\leq 94\%$ on room air or requiring supplemental oxygen or requiring non-invasive or invasive ventilation or extracorporeal membrane oxygenation (ECMO).

Resolved: EAMS Remdesivir acknowledged

2020/053: EAMS: NIVOLUMAB

Nivolumab for treatment as a single agent of adult patients with advanced oesophageal cancer, which is inoperable or has recurred or spread following cancer chemotherapies
Resolved: EAMS Nivolumab acknowledged

STANDING ITEMS

2020/054: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES -

No meetings in April & May

2020/055: FOR ACTION/INFORMATION: LSCNHSFT Drug & Therapeutics Committee Minutes Mar 2020

Minutes acknowledged

DT/41/20 formulary updated as lamotrigine now licensed for bipolar (previously unlicensed use). GPs would like supporting information – CD to ask Julie to follow up.

2020/056: FOR ACTION/INFORMATION: LSCNHSFT Drug & Therapeutics Committee Minutes May 2020

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 15th July 2020 12.30pm via ‘Microsoft Teams’

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 17th JUNE 2020

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed	LR/JV	Feb 20
2020/015	New Product request – Relvar Ellipta® & Anoro Ellipta® - Consultant to attend ELMMB to discuss	CW	Jul 20
2020/020	Formulary Updates – Ranolazine & Ivabradine – Hot Topic to support GP prescribing to be produced with assistance from Dr Singh	JV	Apr 20
2020/031	NICE RECOMMENDATIONS (from Feb) – Patiromer – check traffic light with renal physicians and Central Lancs	CW	Jul 20
2020/044	New Product Request – Wavesense JAZZ BGT Strips – request further information.	CW	Jul 20
2020/048	Formulary Updates – Combination diabetes products - review current use and discuss with diabetes specialists then bring back to ELMMB.	LR / JV	Aug 20
2020/049	Managed Introduction Of New Drugs Policy – comments to LR - Update policy	All LR	26 th June Jul 20